Pritzker/Vlock Family Office

The Pritzker/Vlock Family Office is a financial management firm that oversees a wide range of assets on an international scale. With a focus on diversity in its investment portfolio, PVFO aims to maximize growth and stability for its clients. By carefully managing and strategically allocating resources, the firm offers tailored financial solutions to meet the unique needs of each individual or entity it serves. With a commitment to excellence and a global perspective, the Pritzker/Vlock Family Office provides comprehensive financial management services to help clients achieve their long-term goals.

Elon Boms

Managing Director

13 past transactions

Retia Medical

Series B in 2022
Retia Medical, LLC is a medical device company based in East Lansing, Michigan, specializing in the development of software and hardware for patient monitoring, particularly for high-risk patients. The company offers advanced hemodynamic monitors that accurately measure cardiac output, a crucial health metric indicating the blood flow rate from the heart. These devices are designed for use in critical care settings, such as intensive care units and operating rooms, and are applicable in various high-risk surgeries, including cardiac, neurosurgery, and transplants. Retia Medical's technology, which has been validated through extensive testing, aims to enhance patient care by providing clinicians with essential data for detecting and managing life-threatening conditions like sepsis and multi-organ failure. The company is pursuing FDA approval to launch its innovative monitoring solutions, with the potential for broader applications in emergency rooms and at-home care settings.

Pear Therapeutics

Post in 2021
Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

Iridia

Series B in 2021
Iridia, Inc. is a nanotechnology company based in Carlsbad, California, that specializes in innovative data storage solutions utilizing DNA. Founded in 2016, the company has developed a groundbreaking technology that allows for the reading and writing of data in DNA, leveraging semiconductor fabrication and proprietary enzymology. By integrating DNA polymer synthesis technology with electronic nano-switches, Iridia offers a highly parallel format capable of storing data at exceptionally high densities. This advancement not only reduces the infrastructure requirements for data storage but also addresses environmental concerns associated with traditional storage methods. Iridia aims to provide an affordable and efficient means for businesses to manage large volumes of data sustainably.

BioRez

Seed Round in 2020
Biorez, Inc. is a medical device company specializing in the development of bioresorbable scaffold implants aimed at regenerating functional tissue in vivo. Founded in 2008 and based in New Haven, Connecticut, Biorez offers innovative products such as an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and serves as a superior alternative to cadaver-based materials. The company's technology utilizes a degradable polymer, specifically PLLA, to create implants that stabilize surgical repairs and facilitate the body's natural tissue regeneration, thereby enhancing musculoskeletal outcomes. Among its product lineup is the L-C Ligament® and the biorez GRAFT™, an FDA-cleared device designed for soft tissue augmentation of the rotator cuff. By leveraging this technology, Biorez aims to accelerate patient recovery and improve surgical outcomes in orthopedic procedures.

Shindig

Seed Round in 2017
Shindig is a digital platform that transforms video chat for large-scale, participatory gatherings, allowing all participants to see and interact in a shared online space. The platform enables featured presenters to deliver talks, share multimedia, and teach to live audiences of thousands, while selected audience members can join the hosts on stage for direct interaction. This setup fosters networking and conversation among participants, mimicking the dynamics of in-person events. Shindig has been adopted by a range of high-profile clients, including major corporations and institutions, highlighting its effectiveness for online engagement. The company was founded by Steve Gottlieb, a serial entrepreneur with a notable background in the music industry, and has received significant investment to support its growth. Shindig was recognized with a Cool Vendor Award in Social Collaboration by Gartner in 2017, solidifying its position in the market for virtual and hybrid events.

Gelesis

Private Equity Round in 2015
Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. The company utilizes a mechanobiology technology platform to create its lead product, Gelesis100, an orally administered smart pill that contains hydrogel particles. This product is designed to expand in the stomach, promoting a feeling of fullness and aiding in weight management. Gelesis also offers PLENITY, an FDA-cleared product that assists individuals with weight management. In addition to these offerings, Gelesis has a pipeline of potential therapeutics targeting conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, and chronic idiopathic constipation. Established in 2006, Gelesis aims to provide safe and effective solutions for patients dealing with obesity and related health issues.

ZOZI

Series C in 2015
ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. It offers introductory flight lessons, vineyard tours and wine tasting by horseback, diving for abalone, ice climbing frozen waterfalls, celebrity and athlete experiences, and various accessible adventures. The company also provides weekend getaways and vacation packages for customers. ZOZI was founded in 2007 and is based in San Francisco, California.

Gelesis

Series E in 2014
Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. The company utilizes a mechanobiology technology platform to create its lead product, Gelesis100, an orally administered smart pill that contains hydrogel particles. This product is designed to expand in the stomach, promoting a feeling of fullness and aiding in weight management. Gelesis also offers PLENITY, an FDA-cleared product that assists individuals with weight management. In addition to these offerings, Gelesis has a pipeline of potential therapeutics targeting conditions such as Type 2 diabetes, non-alcoholic fatty liver disease, and chronic idiopathic constipation. Established in 2006, Gelesis aims to provide safe and effective solutions for patients dealing with obesity and related health issues.

Ubiquity Global Services

Series B in 2013
Ubiquity Global Services, Inc. is a multinational outsourcing organization specializing in customer support and business process services. Founded in 2012 and headquartered in New York City, the company operates globally with additional locations in Omaha, Nebraska; Manila and Bacolod in the Philippines; San Salvador, El Salvador; Bogota, Colombia; Amsterdam, the Netherlands; Budapest, Hungary; Wilkes-Barre, Pennsylvania; and Lisbon, Portugal. Ubiquity offers a wide range of services, including call center operations, sales and retention support, social media management, and risk and compliance services such as fraud investigation and chargeback management. The company is recognized for its expertise in the fintech and emerging payments sectors, providing live customer management and interactive voice response solutions. Ubiquity employs advanced technology to enhance operational efficiency and deliver actionable business intelligence, while also developing artificial intelligence and machine learning technologies at its innovation hub in Amsterdam to optimize customer service performance.

Shindig

Seed Round in 2012
Shindig is a digital platform that transforms video chat for large-scale, participatory gatherings, allowing all participants to see and interact in a shared online space. The platform enables featured presenters to deliver talks, share multimedia, and teach to live audiences of thousands, while selected audience members can join the hosts on stage for direct interaction. This setup fosters networking and conversation among participants, mimicking the dynamics of in-person events. Shindig has been adopted by a range of high-profile clients, including major corporations and institutions, highlighting its effectiveness for online engagement. The company was founded by Steve Gottlieb, a serial entrepreneur with a notable background in the music industry, and has received significant investment to support its growth. Shindig was recognized with a Cool Vendor Award in Social Collaboration by Gartner in 2017, solidifying its position in the market for virtual and hybrid events.

ZOZI

Series B in 2011
ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. It offers introductory flight lessons, vineyard tours and wine tasting by horseback, diving for abalone, ice climbing frozen waterfalls, celebrity and athlete experiences, and various accessible adventures. The company also provides weekend getaways and vacation packages for customers. ZOZI was founded in 2007 and is based in San Francisco, California.

Shindig

Pre Seed Round in 2010
Shindig is a digital platform that transforms video chat for large-scale, participatory gatherings, allowing all participants to see and interact in a shared online space. The platform enables featured presenters to deliver talks, share multimedia, and teach to live audiences of thousands, while selected audience members can join the hosts on stage for direct interaction. This setup fosters networking and conversation among participants, mimicking the dynamics of in-person events. Shindig has been adopted by a range of high-profile clients, including major corporations and institutions, highlighting its effectiveness for online engagement. The company was founded by Steve Gottlieb, a serial entrepreneur with a notable background in the music industry, and has received significant investment to support its growth. Shindig was recognized with a Cool Vendor Award in Social Collaboration by Gartner in 2017, solidifying its position in the market for virtual and hybrid events.

Reliant Pharmaceuticals

Series D in 2003
Reliant Pharmaceuticals specializes in the development and marketing of cardiovascular pharmaceutical products. Established in 1999 and headquartered in Liberty Corner, New Jersey, the company offers a range of medications aimed at treating conditions such as hypertension, elevated cholesterol, and acid reflux disease. Its product lineup includes Axid for acid reflux, InnoPran XL and DynaCirc CR for hypertension, Omacor for high triglycerides, and Rythmol SR for coronary heart disease management. Reliant Pharmaceuticals focuses on acquiring and developing branded therapies, targeting mid- to late-stage clinical development for innovative drug delivery technologies and formulations. The company's products are distributed to physicians across primary care and specialized medical fields.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.